The addition of docetaxel to ongoing treatment of men who have survived localised therapy for high-risk prostate cancer appears to confer no extra benefit, a study shows.

The French research showed that adding docetaxel to adjuvant androgen deprivation therapy (ADT) in men with biochemical relapse after primary local treatment does not improve radiological progression-free survival.

Some 15-30% of men undergoing primary local therapy for their prostate cancer will experience a concerning rise in their prostate-specific antigen (PSA) levels in the next decade, yet there is no standard of care for such patients, write the authors in JAMA Oncology.

ADT may be considered, particularly in those deemed at high risk of cancer recurrence, but should a taxane be added?